Pharmaceutical

The fundamentals of developing parenteral drug products 

Advancing to first-in-human clinical trials requires formulation development to design a successful sterile formulation that meets your TPP.

Nov 9, 2024 - 06:00
The fundamentals of developing parenteral drug products 
Advancing to first-in-human clinical trials requires formulation development to design a successful sterile formulation that meets your TPP.
Read the original article

Tags:

Previous Article

AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial

Next Article

Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Eli Lilly’s Alzheimer’s therapy slowed patients’ rate of cognitive decline, data show

STAT+: Eli Lilly’s Alzheimer’s therapy slowed patients’...

May 3, 2023

STAT+: Pharmalittle: FDA approves first gene therapy for Duchenne muscular dystrophy; states join FTC to stop Amgen deal

STAT+: Pharmalittle: FDA approves first gene therapy fo...

Jun 24, 2023

STAT+: Oracle’s Cerner Enviza launches a new effort to use AI to study asthma drug safety

STAT+: Oracle’s Cerner Enviza launches a new effort to ...

Apr 11, 2023